Pyrimidine compounds

A method for treating an interleukin-12 overproduction-related disorder selected from rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus, comprising administering to a subject in need thereof an effective amount of the compound of formula (I):

• wherein
• R1 is
• aryl, or heteroaryl;
• each of R2 and R4, independently, is Rc, halogen, nitro, cyano, isothionitro, SRc, or ORc;
• or R2 and R4, taken together, is carbonyl;
• R3 is Rc, alkenyl, alkynyl, ORc, OC(O)Rc, SO2Rc, S(O)Rc, S(O2)NRcRd, SRc, NRcRd, NRcCORd, NRcC(O)ORd, NRcC(O)NRcRd, NRcSO2Rd, CORc, C(O)ORc, or C(O)NRcRd;
• R5 is H or alkyl;
• n is 0, 1, 2, 3, 4, 5, or 6;
• X is O, S, S(O), S(O2), or NRc;
• Y is a covalent bond, CH2, C(O), C═N—Rc, C═N—ORc, C═N—SRc, O, S, S(O), S(O2), or NRc;
• Z is N or CH;
• one of U and V is N, and the other is CRc;
• and
• W is O, S, S(O), S(O2), NRc, or NC(O)Rc
• in which each of Ra and Rb, independently, is H, alkyl, aryl, or heteroaryl;
• and each of Rc and Rd, independently, is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl;
• or a pharmaceutically acceptable salt thereof.